3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Recruiting
6
Active not recruiting
6
Unknown
2
Terminated
2
Withdrawn
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Head & Neck
1
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder Neoplasms
1
Neoplasms
1
Head and Neck Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
Cisplatin
352
Oxaliplatin
262
Capecitabine
258
Radiotherapy
240
Gemcitabine
223
Docetaxel
223
Carboplatin
223
Drug Therapy
219
Cyclophosphamide
219
Paclitaxel
205
apatinib
201
Bevacizumab
196
camrelizumab
190
Fluorouracil
188
sintilimab
133
Irinotecan
125
Blood Specimen Collection
125
Dexamethasone
123
Etoposide
119
Radiosurgery
118
toripalimab
117
Surgical Procedures, Operative
115
pembrolizumab
112
Pemetrexed
108
anlotinib
105
S 1 (combination)
105
Leucovorin
102
Surveys and Questionnaires
101
Nivolumab
98
tislelizumab
96
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Unknown
×
OTHER
×
Tiragolumab
×
Clear all
NCT05259319
2023-10-17
IMMUNOs-SBRT
Centre Georges Francois Leclerc
Phase 1
Unknown
92 enrolled
NCT05034055
2021-09-05
SKYROCKET
Yonsei University
Phase 2
Unknown
45 enrolled